KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non‒Small-Cell Lung Cancer

التفاصيل البيبلوغرافية
العنوان:	KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non‒Small-Cell Lung Cancer
المؤلفون:	Jabbour, S.K., Cho, B.C., Bria, E., Kato, T., Bhosle, J., Gainor, J.F., Reguart, N., Wang, L., Morgensztern, D., Gurary, E.B., Ashraf, T.B., Lara-Guerra, H., Reck, M.
المصدر:	In International Journal of Radiation Oncology, Biology, Physics 1 November 2021 111(3) Supplement:e440-e441
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	03603016
DOI:	10.1016/j.ijrobp.2021.07.1246